Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects

Clinical and Experimental Allergy

Volumn 35, Issue 7, 2005, Pages 880-883

  Passalacqua, Giovanni ^a,d   Altrinetti, V ^a   Mariani, G ^b   Falagiani, P ^c   Mistrello, G ^c   Brizzolara, R ^a   Canonica, G W ^a   Bagnasco, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Lofarma SpA   (Italy)

^d Padiglione Maragliano ^*  (Italy)

Author keywords

Allergic rhinitis; Local nasal immunotherapy; Par j 1; Pharmacokinetics; Radiolabelling

Indexed keywords

ALLERGEN; IODINE 123; PAR J 1 ALLERGEN I 123; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GASTROINTESTINAL ABSORPTION; GEL CHROMATOGRAPHY; HUMAN; IMMUNOTHERAPY; ISOTOPE LABELING; NOSE; PARIETARIA; PHARYNX; PRIORITY JOURNAL; RADIOACTIVITY; SCINTIGRAPHY;

ADMINISTRATION, INTRANASAL; ALLERGENS; HUMANS; IMMUNIZATION; IODINE RADIOISOTOPES; NASAL CAVITY; PARIETARIA; PHARYNX; PLANT PROTEINS; RHINITIS;

EID: 22744441333     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.2226.x     Document Type: Article

References (22)

1. Bousquet J, Lockey R, Mailing HJ, eds. World Health Organization Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 54 (Suppl.):2-18.
2. Malling HJ., ed. EAACI Position Paper on local immunotherapy. Allergy 1998; 53:933.
3. Bousquet J, Van Cauwenberge P., eds. Allergic rhinits and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl. 12):S83-5.
4. Taylor G, Shivalkar E. Changes in nasal airways resistance on antigenic challenge in allergic rhinitis. Clin Allergy 1971; 1:63-73.
5. Ciprandi G, Ricca V, Landi M, Passalacqua G, Bagnasco M, Canonica GW. Allergen specific nasal challenge: response kinetic of clinical and inflammatory events to rechallenge. Int Arch Allergy Immunol 1998; 115:157-61.
6. Canonica GW, Passalacqua G. Non injection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:437-48.
7. Giannarini L, Maggi E. Decrease of allergen-specific T-cell response induced by local nasal immunotherapy. Clin Exp Allergy. 1998; 28:404-12.
8. Passalacqua G, Albano M, Pronzato C, Riccio A, Falagiani P, Canonica GW. Nasal immunotherapy to Parietaria: long term follow up of a double blind study. Clin Exp Allergy 1997; 27:904-8.
9. Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4-5 years. J Invest Allergol Clin Immunol 2003; 13:228-31.
10. Bagnasco M, Mariani G, Passalacqua G et al. Absorption and distribution kinetics of the mayor Parietaria allergen administered by noninjectable routes to healthy human beings. J Allergy Clin Immunol 1997; 100:121-9.
11. Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in serum after intranasal treatment of normal rabbits with P. judaica extracts. Allergy 1991; 46:52-5.
12. Fraker PJ, Speck JC. Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,5-tetrachloro-3a, 6a-diphnyl-glycouril. Biochem Biophys Res Commun 1978; 80:849-57.
13. Buckle FB, Cohen AB. Nasal mucosal hyperpermeability to macromolecules in atopic rhinitis and extrinsic asthma. J Allergy Clin Immunol 1975; 55:213-21.
14. Bagnasco M, Passalacqua G, Villa G et al. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31:54-60.
15. D'Amato G, Spieksma FT, Liccardi G et al. Pollen-related allergy in Europe. Allergy 1998; 53:567-78.
16. Liccardi G, Visone A, Russo M, Saggese M, D'Amato M, D'Amato G. Parietaria pollinosis: clinical and epidemiological aspects. Allergy Asthma Proc 1996; 17:23-9.
17. Andri L, Senna GE, Betteli C et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy 1992; 47:318-23.
18. Asturias JA, Gomez-Bayon N, Eseverri JL, Martinez A. Par j 1 and Par j 2, the major allergens from Parietaria judaica pollen, have similar immunoglobulin E epitopes. Clin Exp Allergy 2003; 33:518-24.
19. Soane RJ, Carney AS, Jones NS et al. The effect of the nasal cycle on mucociliary clearance. Clin Otolaryngol. 2001; 26:9-15.
20. Mori S, Fujieda S, Kimura Y, Takahashi N, Saito H. Nasal challenge activates the mucociliary transport system on not only the ipsilateral but also the contralateral side of the nose in patients with perennial allergic rhinitis. J Otorhinolaryngol Relat Spec 2000; 62:303-6.
21. Ciprandi G, Ricca V, Pronzato C, Passalacqua G, Bagnasco M, Canonica GW. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994; 150:1653-9.
22. Litvyakova LI, Baraniuk JN. Nasal provocation testing: a review. Ann Allergy Asthma Immunol 2001; 86:355-64.